The gut microbiota from CRC patients significantly conveyed resistance to anti-PD-1 mAb in these tumor-bearing mice, compared to the mice receiving microbiota from healthy controls (Figure 1F-H). This evidence concerns the gene PDCD1 and colorectal carcinoma.